Autolus Therapeutics plc - American Depositary Share (AUTL): Price and Financial Metrics
AUTL Price/Volume Stats
| Current price | $2.34 | 52-week high | $5.00 |
| Prev. close | $2.26 | 52-week low | $1.11 |
| Day low | $2.28 | Volume | 2,654,800 |
| Day high | $2.43 | Avg. volume | 1,754,559 |
| 50-day MA | $1.49 | Dividend yield | N/A |
| 200-day MA | $2.60 | Market Cap | 622.77M |
AUTL Stock Price Chart Interactive Chart >
Autolus Therapeutics plc - American Depositary Share (AUTL) Company Bio
Autolus Therapeutics is developing a pipeline of advanced programmable T cell treatment candidates for blood and solid tumor cancers. Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I), or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma. The company is based in London, England.
AUTL Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AUTL Price Returns
| 1-mo | 73.33% |
| 3-mo | 16.42% |
| 6-mo | -20.68% |
| 1-year | -41.50% |
| 3-year | -17.31% |
| 5-year | -82.14% |
| YTD | -0.43% |
| 2024 | -63.51% |
| 2023 | 238.95% |
| 2022 | -63.39% |
| 2021 | -41.95% |
| 2020 | -32.27% |